Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory

Executive Summary

Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.

You may also be interested in...



Setback For Glenmark As FDA Hands Out CRL For Ryaltris

India's Glenmark gets US Complete Response Letter for Ryaltris but emphasizes the FDA hasn’t faulted the clinical data for the product, and that the action won’t impact recent alliances for the rhinitis asset.

Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel